Ann: Appendix 4C - quarterly, page-28

I'm just wondering if they're waiting for the human trials to start. Maybe the possible JV partner(s), want to see how things go , before putting their funding in.
Admedus said in Feb 2019 that thing s were going very well and human trials were looking close.

On the 24th of June 2019, in the ADAPT ASX article, the following was stated;

According to AHZ’s CEO, Wayne Paterson, “the study reinforces the clinical superiority of CardioCel® which uses our proprietary ADAPT® tissue. This large body of independent data, published in a highly respected peer-review journal, is a very important milestone. The data will support further market adoption not only for CardioCel® but our entire ADAPT® portfolio. “It also reinforces the clinical and commercial potential of our 3D single piece aortic valve and TAVR devices in development. Each will have the same anti-calcification properties, key differentiators and improvement on existing solutions. We are now rapidly progressing towards first-in-human studies and look forward to providing an update in due course”.
---------------------------------
If we get the result we expect, then this could be our saviour.
For a product like this it must be worth a substantial sum to become a JV partner, even for a company on it's knees.

I'm not interested in all the talk about what it's been done or whose to blame, it's been said and repeated so many times, its not funny.
I'm controlling what I can and keeping a watchful eye on the ASX releases for AHZ, that something good is going to happen.
If it doesn't, I'll just have to try a little harder to make up for the loss.
So far the FAT LADY HASN"T STARTED SINGING, so life is good.
I just lost my loving Dad last week , two months of 99. I know what is more important to me.

Regards
Dabru